

Association News and Announcements

SHORT COURSES

Westin Peachtree Plaza Hotel
Atlanta, Georgia
Sunday, October 22

Registration for Short Courses is by pre-registration only. There will be no on-site registration. Registration for each Short Course is limited to 85 participants. A minimum of 50 registrants are required to present a course. If the minimum number of registrants are not received by September 31, 1989, the course will be canceled. Pharmaceutical Continuing Education credit will not be available for "Effective Grant Writing."

Application of Polymeric Materials in the Controlled Delivery of Pharmaceutical Products. Coordinators: David H. Bergstrom, CIBA-GEIGY Corp. (201-277-5133) and David J. Mazzo, Baxter Healthcare Corp. (312-546-6311). As the need to control delivery of pharmaceutical products increases, so does the application of polymeric materials in drug formulation. This course will introduce the attendees to the more promising application of polymers to controlled drug delivery such as diffusion control, drug targeting, stimuli-sensitive membranes, encapsulation and/or steric control of retention. Both basic principles and recent advances in the use of polymers as drug vehicles and/or administration rate controllers will be discussed. *General Principles of Polymer Chemistry Pertinent to Drug Delivery*, F. W. Harris, University of Akron; *Application of Polymers in Drug Delivery: Diffusion Control Approaches*, R. S. Langer, M.I.T. and R. Segal, University of California, San Francisco; *Use of Polymers in Drug Targeting*, J. Kopecek, University of Utah; *Drug Delivery via Polymers which Are Sensitive to External Physical or Chemical Stimuli*, L. Miller, University of Minnesota; *Polymeric Materials with Bioactivity*, K. Petrak, CIBA-GEIGY; *Polymeric Considerations in Bioadhesion*, J. R. Robinson, University of Wisconsin. Registration fee: \$295.00.

Effective Grant Writing. Coordinator: Linda E. Gustavson, Abbott Laboratories (312-937-9106). Note: this is the only half-day short course offered and no Continuing Education credit will be offered. Beyond the importance of formulating a sound and creative scientific plan, there are a variety of things that can be done to increase the chances that a grant proposal will be funded. The purpose of this half-day course will be to share with grant writers the methods which can help to mold their scientific ideas into the best possible grant proposals. The leaders of this course have many years of experience writing and reviewing grants for the NIH and other sources. The course format will provide ample time for questions. *The NIH Application—From Sub-*

mission to Decision, H.-L. Fung, State University of New York; *Grantsmanship—Dos and Don'ts*, L. Z. Benet, University of California, San Francisco; *Industrial Perspective on Grants: The Glaxo Cardiovascular Research Grant Program*, D. R. Savello, Glaxo. Registration fee: \$30.00.

Formulation and Delivery of Proteins and Peptides. Coordinators: Barbara J. Floy, Syntex Research (415-855-6306) and Paul L. Pluta, Abbott Laboratories (312-937-5073). Advances in biotechnology have resulted in the development of many new peptide and protein compounds. These compounds offer new and unique challenges in the areas of delivery, formulation development, and product manufacture. This course will review approaches to preformulation, formulation development, and scale-up manufacture of proteins and peptides. Alternative delivery approaches and their advantages and disadvantages will also be discussed. This course will be valuable for development scientists facing the challenge of working with peptides and proteins. *Preformulation and Early Formulation of Bovine Somatotropin*, M. J. Hageman, Upjohn; *Formulation of Proteins and Peptides*, K. Iqbal, Hoffman-La Roche; *Processing Considerations in Formulation of Peptides and Proteins*, R. Peeples, Sandoz; *Ophthalmic Delivery of Peptides*, V. H. L. Lee, University of Southern California; *Intranasal and Buccal Delivery of Peptides*, N. F. H. Ho, Upjohn. Registration fee: \$295.00.

New Drug Applications—Overview and Update. Coordinator: Ingrid M. Johnson, Baxter Healthcare Corp. (312-965-4700). A new drug entity is introduced into the U.S. marketplace following a rigorous, reasonably well-defined but continuously evolving regulatory approval process. The effective organization and management of the drug development program has a direct correlation with the quality of the New Drug Application (NDA) submitted. This short course is designed to familiarize participants with the principle elements of the new drug approval process as presently defined. Areas discussed will include chemical synthesis, drug safety and efficacy, preclinical pharmacology, drug metabolism, pharmaceutical control and manufacturing, clinical evaluation, and assembly into a final document. Recent updates to the application/approval process will be highlighted. *Bulk Chemical Synthesis and Characterization*, A. G. Ramsey; *Pharmacology/Drug Safety*, R. Patterson, Abbott; *Biopharmaceutical/Pharmacokinetics*, R. J. Wills, Hoffmann-La Roche; *Pharmaceutical Control and Manufacture*, L. Shtohryn, Glaxo; *Clinical Study Information*, T. P. Gibson, Merck, Sharp and Dohme Research; *Assembly into a Final Document*, K. Church, Genesia; *Perspective of the Regulatory Agency*, M. D. Tyson, FDA. Registration fee: \$295.00.

Registration forms are included in the AAPS Preliminary Program. If you are not an AAPS member, call AAPS at 703-548-3000 for registration materials.